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Abstract. The Alzheimer’s Disease Prediction Of Longitudinal Evo-
lution (TADPOLE) Challenge compares the performance of algorithms
at predicting the future evolution of individuals at risk of Alzheimer’s
disease. TADPOLE Challenge participants train their models and al-
gorithms on historical data from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) study. Participants are then required to make forecasts
of three key outcomes for ADNI-3 rollover participants: clinical diagno-
sis, Alzheimer’s Disease Assessment Scale Cognitive Subdomain (ADAS-
Cog 13), and total volume of the ventricles – which are then compared
with future measurements. Strong points of the challenge are that the
test data did not exist at the time of forecasting (it was acquired after-
wards), and that it focuses on the challenging problem of cohort selection
for clinical trials by identifying fast progressors. The submission phase of
TADPOLE was open until 15 November 2017; since then data has been
acquired until April 2019 from 219 subjects with 223 clinical visits and
150 Magnetic Resonance Imaging (MRI) scans, which was used for the
evaluation of the participants’ predictions. Thirty-three teams partici-
pated with a total of 92 submissions. No single submission was best at
predicting all three outcomes. For diagnosis prediction, the best forecast
(team Frog), which was based on gradient boosting, obtained a multi-
class area under the receiver-operating curve (MAUC) of 0.931, while for
ventricle prediction the best forecast (team EMC1 ), which was based on
disease progression modelling and spline regression, obtained mean ab-
solute error of 0.41% of total intracranial volume (ICV). For ADAS-Cog
13, no forecast was considerably better than the benchmark mixed effects
model (BenchmarkME), provided to participants before the submission
deadline. Further analysis can help understand which input features and
algorithms are most suitable for Alzheimer’s disease prediction and for
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aiding patient stratification in clinical trials. The submission system re-
mains open via the website: https://tadpole.grand-challenge.org/
Keywords: Alzheimer’s Disease, Future prediction, Community Chal-
lenge
1 Introduction
Accurate prediction of the onset of Alzheimer’s disease (AD) and its longitudinal
progression is important for care planning and for patient selection in clinical
trials. Early detection will be critical in the successful administration of dis-
ease modifying treatments during presymptomatic phases of the disease prior to
widespread brain damage, i.e. when pathological amyloid and tau accumulate [1].
Moreover, accurate prediction of the evolution of subjects at risk of Alzheimer’s
disease will help to select homogeneous patient groups for clinical trials, thus
reducing variability in outcome measures that can obscure positive effects on
subgroups of patients who were at the right stage to benefit.
Fig. 1: TADPOLE Challenge design. Participants are required to train a pre-
dictive model on a training dataset (D1 and/or others) and make forecasts for
different datasets (D2, D3) by the submission deadline. Evaluation will be per-
formed on a test dataset (D4) that is acquired after the submission deadline.
Several approaches for predicting AD-related target variables (e.g. clinical
diagnosis, cognitive/imaging biomarkers) have been proposed which leverage
multimodal biomarker data available in AD. Traditional longitudinal approaches
based on statistical regression model the relationship of the target variables with
other known variables, such as clinical diagnosis [2], cognitive test scores [3], or
time to conversion between diagnoses [4]. Another approach involves supervised
machine learning techniques such as support vector machines, random forests,
and artificial neural networks, which use pattern recognition to learn the rela-
tionship between the values of a set of predictors (biomarkers) and their labels
(diagnoses). These approaches have been used to discriminate AD patients from
cognitively normal individuals [5], and for discriminating at-risk individuals who
convert to AD in a certain time frame from those who do not [6]. The emerging
approach of disease progression modelling [7,8] aims to reconstruct biomarker
trajectories or other disease signatures across the disease progression timeline,
without relying on clinical diagnoses or estimates of time to symptom onset.
Such models show promise for predicting AD biomarker progression at group
and individual levels. However, previous evaluations within individual publica-
tions are not systematic and reliable because: (1) they use different data sets or
subsets of the same dataset, different processing pipelines and different evalua-
tion metrics and (2) over-training can occur due to heavy use of popular training
datasets. Currently we lack a comprehensive comparison of the capabilities of
these methods on standardised tasks relevant to real-world applications.
Community challenges have consistently proven effective in moving forward
the state-of-the-art in technology to address specific data-analysis problems by
providing platforms for unbiased comparative evaluation and incentives to max-
imise performance on key tasks. For Alzheimer’s disease prediction in particular,
previous challenges include the CADDementia challenge [9] which aimed to iden-
tify clinical diagnosis from MRI scans. A similar challenge, the “International
challenge for automated prediction of MCI from MRI data“ [10] asked partic-
ipants to predict diagnosis and conversion status from extracted MRI features
of subjects from the ADNI study [11]. Yet another challenge, The Alzheimer’s
Disease Big Data DREAM Challenge [12], asked participants to predict cogni-
tive decline from genetic and MRI data. However, most of these challenges have
not evaluated the ability of algorithms to predict clinical diagnosis and other
biomarkers at future timepoints and largely used training data from a limited set
of modalities. The one challenge that asked participants to estimate a biomarker
at future timepoints (cognitive decline in one of the DREAM sub-challenges)
used only genetic and cognitive data for training, and aimed to find genetic loci
that could predict cognitive decline. Therefore, standardised evaluation of algo-
rithms needs to be done on biomarker prediction at future timepoints, with the
aim of improving clinical trials through enhanced patient stratification.
The Alzheimer’s Disease Prediction Of Longitudinal Evolution (TADPOLE)
Challenge aims to identify the data, features and approaches that are most pre-
dictive of future progression of subjects at risk of AD. The challenge focuses
on forecasting the evolution of three key AD-related domains: clinical diagnosis,
cognitive decline, and neurodegeneration (brain atrophy). In contrast to previous
challenges, our challenge is designed to inform clinical trials through identifica-
tion of patients most likely to benefit from an effective treatment, i.e., those
at early stages of disease who are likely to progress over the short-to-medium
term (defined as 1-5 years). Since the test data did not exist at the time of fore-
cast submissions, the challenge provides a performance comparison substantially
less susceptible to many forms of potential bias than previous studies and chal-
lenges. The design choices were published [13] before the test set was acquired
and analysed. TADPOLE also goes beyond previous challenges by drawing on
a vast set of multimodal measurements from ADNI which support prediction of
AD progression.
This article presents the design of the TADPOLE Challenge and outlines
preliminary results.
2 Competition Design
The aim of TADPOLE is to predict future outcome measurements of subjects
at-risk of AD, enrolled in the ADNI study. A history of informative measure-
ments from ADNI (imaging, psychology, demographics, genetics, etc.) from each
individual is available to inform forecasts. TADPOLE participants were required
to predict future measurements from these individuals and submit their predic-
tions before a given submission deadline. Evaluation of these forecasts occurred
post-deadline, after the measurements had been acquired. A diagram of the
TADPOLE flow is shown in Fig 1.
TADPOLE challenge participants were required to make month-by-month
forecasts of three key biomarkers: (1) clinical diagnosis which is either cogni-
tively normal (CN), mild cognitive impairment (MCI) or probable Alzheimer’s
disease (AD); (2) Alzheimer’s Disease Assessment Scale Cognitive Subdomain
(ADAS-Cog 13) score; and (3) ventricle volume (divided by intra-cranial vol-
ume). TADPOLE forecasts are required to be probabilistic and some evaluation
metrics will account for forecast probabilities provided by participants.
3 ADNI data aggregation and processing
TADPOLE Challenge organisers provided participants with a standard ADNI-
derived dataset (available via the Laboratory Of NeuroImaging data archive at
adni.loni.usc.edu) to train algorithms, removing the need for participants to
pre-process the ADNI data or merge different spreadsheets. Software code used
to generate the standard datasets is openly available on Github8. The challenge
data includes: (1) CSF markers of amyloid-beta and tau deposition; (2) various
imaging modalities such as magnetic resonance imaging (MRI), positron emis-
sion tomography (PET) using several tracers: FDG (hypometabolism), AV45
(amyloid), AV1451 (tau) as well as diffusion tensor imaging (DTI); (3) cognitive
assessments such as ADAS-Cog 13 acquired in the presence of a clinical expert;
(4) genetic information such as alipoprotein E4 (APOE4) status extracted from
DNA samples; and (5) general demographic information such as age and gender.
Extracted features from this data were merged into a final spreadsheet and made
available online.
The imaging data was pre-processed with standard ADNI pipelines. For
MRI scans, this included correction for gradient non-linearity, B1 non-uniformity
correction and peak sharpening9. Meaningful regional features such as volume
8 https://github.com/noxtoby/TADPOLE
9 see http://adni.loni.usc.edu/methods/mri-analysis/mri-pre-processing
and cortical thickness were extracted using Freesurfer. Each PET image (FDG,
AV45, AV1451), which consists of a series of dynamic frames, had its frames
co-registered, averaged across the dynamic range, standardised with respect to
the orientation and voxel size, and smoothed to produce a uniform resolution of
8mm full-width/half-max (FWHM)10. Standardised uptake value ratio (SUVR)
measures for relevant regions-of-interest were extracted after registering the PET
images to corresponding MR images using SPM5. DTI scans were corrected for
head motion and eddy-current distortion, skull-stripped, EPI-corrected, and fi-
nally aligned to the T1 scans. Diffusion tensor summary measures were estimated
based on the Eve white-matter atlas.
3.1 TADPOLE Datasets
In order to evaluate the effect of different methodological choices, we prepared
four “standard“ data sets: the D1 standard training set contains longitudinal
data from the entire ADNI history; the D2 longitudinal prediction set contains
all available data from the ADNI rollover individuals, for whom challenge partic-
ipants are asked to provide forecasts; the D3 cross-sectional prediction set con-
tains a single (most recent) time point and a limited set of variables from each
rollover individual – this represents the information typically available in a clin-
ical trial; the D4 test set contains visits from ADNI rollover subjects after 1
Jan 2018, which contain at least one of the following: diagnostic status, ADAS
score, or ventricle volume from MRI – this dataset did not exist at the time of
submitting forecasts. Full demographics for D1–D4 are given in Table 1.
4 Submissions and evaluation
The challenge had a total of 33 participating teams, who submitted a total of 58
forecasts from D2, 34 forecasts from D3, and 6 forecasts from custom prediction
sets. Table 2 summarises the top-3 winner methods in terms of input features
used, handling of missing data and predictive models: Frog used a gradient boost-
ing method, which combined many weak predictors to build a strong predictor;
EMC1 derived a “disease state“ variable aggregating multiple features together
and then used an SVM and 2D splines for prediction, while VikingAI used a
latent-time parametric model with subject- and feature-specific parameters – see
[14] for full method details. We also describe three benchmark models which were
provided to participants at the start of the challenge: (i) BenchmarkLastVisit
uses the measurement at the last available visit, (ii) BenchmarkME-APOE uses
a mixed effects model with APOE status as covariate and (iii) BenchmarkSVM
uses an out-of-the-box support vector machine (SVM) and regressor for forecast.
For evaluation of clinical status predictions, we used similar metrics to those
that proved effective in the CADDementia challenge [9]: (i) the multiclass area
under the receiver operating curve (MAUC); and (ii) the overall balanced classi-
fication accuracy (BCA). For ADAS and ventricle volume, we used three metrics:
10 see http://adni.loni.usc.edu/methods/pet-analysis/pre-processing
Measure D1 D2 D3 D4
Subjects 1667 896 896 219
Cognitively Normal
Number (% total) 508 (30%) 369 (41%) 299 (33%) 94 (42%)
Visits per subject 8.3 ± 4.5 8.5 ± 4.9 1.0 ± 0.0 1.0 ± 0.2
Age 74.3 ± 5.8 73.6 ± 5.7 72.3 ± 6.2 78.4 ± 7.0
Gender (% male) 48% 47% 43% 47%
MMSE 29.1 ± 1.1 29.0 ± 1.2 28.9 ± 1.4 29.1 ± 1.1
Converters (% total CN) 18 (3.5%) 9 (2.4%) - -
Mild Cognitive Impairment
Number (% total) 841 (50.4%) 458 (51.1%) 269 (30.0%) 90 (41.1%)
Visits per subject 8.2 ± 3.7 9.1 ± 3.6 1.0 ± 0.0 1.1 ± 0.3
Age 73.0 ± 7.5 71.6 ± 7.2 71.9 ± 7.1 79.4 ± 7.0
Gender (% male) 59.3% 56.3% 58.0% 64.4%
MMSE 27.6 ± 1.8 28.0 ± 1.7 27.6 ± 2.2 28.1 ± 2.1
Converters (% total MCI) 117 (13.9%) 37 (8.1%) - 9 (10.0%)
Alzheimer’s Disease
Number (% total) 318 (19.1%) 69 (7.7%) 136 (15.2%) 29 (13.2%)
Visits per subject 4.9 ± 1.6 5.2 ± 2.6 1.0 ± 0.0 1.1 ± 0.3
Age 74.8 ± 7.7 75.1 ± 8.4 72.8 ± 7.1 82.2 ± 7.6
Gender (% male) 55.3% 68.1% 55.9% 51.7%
MMSE 23.3 ± 2.0 23.1 ± 2.0 20.5 ± 5.9 19.4 ± 7.2
Converters (% total AD) - - - 9 (31.0%)
Table 1: Summary of TADPOLE datasets D1–D4. Each subject has been allo-
cated to either Cognitively Normal, MCI or AD group based on diagnosis at the
first available visit within each dataset.
Submission Extra†
Features
Nr. of
features
Missing data
imputation
Diagnosis
prediction
ADAS/Vent.
prediction
Frog most
features
70+420* none gradient
boosting
gradient
boosting
EMC1-Std MRI,
ASL,
cognitive
250 nearest
neighbour
DPM SVM
2D-spline
DPM
2D-spline
VikingAI-Sigmoid MRI,
cognitive,
tau
10 none DPM +
ordered logit
DPM
BenchmarkLastVisit - 3 none constant model constant model
BenchmarkME-APOE APOE 4 none Gaussian
model
linear mixed
effects model
BenchmarkSVM age,
APOE
6 mean of
previous values
SVM support vector
regressor
Table 2: Summary of benchmarks and top-3 methods used in the TADPOLE
submissions. DPM – disease progression model. (†) Aside from the three target
biomarkers (*) Augmented features: e.g. min/max, trends, moments.
(i) mean absolute error (MAE), (ii) weighted error score (WES) and (iii) cov-
erage probability accuracy (CPA). BCA and MAE focus purely on prediction
accuracy ignoring confidence, MAUC and WES include confidence, while CPA
provides an assessment of the confidence interval only. Complete formulations
for these can be found in Table 3, with detailed explanations in the TADPOLE
design paper [13]. To compute an overall rank, we first calculated the sum of
ranks from MAUC, ADAS MAE and Ventricle MAE for each submission, and
the overall ranking was derived from these sums of ranks.
Formula Definitions
mAUC =
2
L(L−1)
∑L
i=2
∑i
j=1 Aˆ(ci, cj)
ni, nj – number of points from class i and j. Sij – the sum
of the ranks of the class i test points, after ranking all the
class i and j data points in increasing likelihood of
belonging to class i, L – number of data points
BCA =
1
2L
∑L
i=1
[
TP
TP+FN
+ TN
TN+FP
] TPi, FPi, TNi, FNi the number of true positives, falsepositives, true negatives and false negatives for class i L
number of data points
MAE = 1
N
∑N
i=1
∣∣∣M˜i −Mi∣∣∣ Mi is the actual value in individual i in future data. M˜i isthe participant’s best guess at Mi and N is the number of
data points
WES =
∑N
i=1 C˜i|M˜i−Mi|∑N
i=1 C˜i
Mi, M˜i and N defined as above. C˜i = (C+ −C−)−1, where
[C−, C+] is the 50% confidence interval
CPA = |ACP − 0.5| actual coverage probability (ACP) - the proportion of
measurements that fall within the 50% confidence interval.
Table 3: TADPOLE performance metric formulas and definitions for the terms.
5 Results
While full results can be found on the TADPOLE website [14], here we only
include the top-3 winners. Table 4 compiles all metrics for top-3 TADPOLE
forecasts from the D2 prediction set. The best overall performance was obtained
by team Frog, with a clinical diagnosis MAUC of 0.931, ADAS MAE of 4.85 and
Ventricle MAE of 0.45. Among the benchmark methods, BenchmarkME-APOE
had the best overall rank of 18, obtaining an MAUC of 0.82, ADAS MAE of
4.75 and Ventricle MAE of 0.57. In terms of diagnosis predictions, Frog had
an overall MAUC score of 0.931. For ADAS prediction, BenchmarkME-APOE
had the best MAE of 4.75. For Ventricle prediction, EMC1-Std had the best
MAE of 0.41 and WES of 0.29. In terms of the most accurate confidence interval
estimates, VikingAI achieved the best CPA scores of 0.02 for ADAS and 0.2 for
Ventricles.
Overall Diagnosis ADAS Ventricles (% ICV)
Submission Rank MAUC BCA MAE WES CPA MAE WES CPA
Frog 1 0.931 0.849 4.85 4.74 0.44 0.45 0.33 0.47
EMC1-Std 2 0.898 0.811 6.05 5.40 0.45 0.41 0.29 0.43
VikingAI-Sigmoid 3 0.875 0.760 5.20 5.11 0.02 0.45 0.35 0.20
BenchmarkME-APOE 18 0.822 0.749 4.75 4.75 0.36 0.57 0.57 0.40
BenchmarkSVM 34 0.836 0.764 6.82 6.82 0.42 0.86 0.84 0.50
BenchmarkLastVisit 40 0.774 0.792 7.05 7.05 0.45 0.63 0.61 0.47
Table 4: Ranked forecasting scores for benchmark models and top-3 TADPOLE
submissions.
6 Discussion
In the current work we have outlined the design and key results of TADPOLE
Challenge, which aims to identify algorithms and features that can best predict
the evolution of Alzheimer’s disease. Despite the small number of converters
in the training set, the methods were able to accurately forecast the clinical
diagnosis and ventricle volume, although they found it harder to forecast cogni-
tive test scores. Compared to the benchmark models, the best submissions had
considerably smaller errors that represented only a small fraction of the errors
obtained by benchmark models (0.42 for clinical diagnosis MAUC and 0.71 for
ventricle volume MAE). For clinical diagnosis, this suggests that more than half
of the subjects originally misdiagnosed by the best benchmark model (Bench-
markSVM ) are now correctly diagnosed with the new methods. Moreover, the
results suggest that we do not have a clear winner on all categories. While team
Frog had the best overall submission with the lowest sum of ranks, for each
performance metric individually we had different winners.
Additional work currently in progress [14] suggests that consensus methods
based on averaging predictions from all participants perform better than any sin-
gle individual method. This demonstrates the power of TADPOLE in achieving
state-of-the-art prediction accuracy through crowd-sourcing prediction models.
The TADPOLE Challenge and its preliminary results presented here are of
importance for the design of future clinical trials and more generally may be ap-
plicable to a clinical setting. The best algorithms identified here could be used
for subject selection or stratification in clinical trials, e.g. by enriching trial in-
clusion with fast progressors to increase the statistical power to detect treatment
changes. Alternatively, a stratification could be implemented based on predicted
“fast progressors“ and “slow progressors“ to reduce imbalances between arms.
In order to make these models applicable to clinical settings, application in a
clinical sample should be tested outside ADNI and further validation in a sub-
ject population with post-mortem confirmation would be desirable, as clinical
diagnosis of probable AD only has moderate agreement with gold-standard neu-
ropathological post-mortem diagnosis (70.9% – 87.3% sensitivity and 44.3% –
70.8% specificity, according to [15]). We hope such a validation will be possi-
ble in the future, with the advent of neuropathological confirmation in large,
longitudinal, multimodal datasets such as ADNI.
In future work, we plan to analyse which features and methods were most
useful for predicting AD progression, and assess if the results are sufficient to
improve stratification for AD clinical trials. We also plan to evaluate the impact
and interest of the first phase of TADPOLE within the community, to guide
decisions on whether to organise further submission and evaluation phases.
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